Cargando…

Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist

A novel clinical study design was used to evaluate the blockade of a selective short-acting μ-opioid agonist (remifentanil) in 24 opioid-experienced subjects. Samidorphan (3-carboxamido-4-hydroxynaltrexone) is a novel opioid modulator with μ-antagonist properties. Objective (pupil diameter) and subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shram, Megan J., Silverman, Bernard, Ehrich, Elliot, Sellers, Edward M., Turncliff, Ryan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Original Contributions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415969/ https://www.ncbi.nlm.nih.gov/pubmed/25928699 http://dx.doi.org/10.1097/JCP.0000000000000320

Ejemplares similares

A Review of Samidorphan: A Novel Opioid Antagonist
por: Chaudhary, Amna Mohyud Din, et al.
Publicado: (2019)

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies
por: Fava, Maurizio, et al.
Publicado: (2018)

Evaluation of Opioid Modulation in Major Depressive Disorder
por: Ehrich, Elliot, et al.
Publicado: (2015)

In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations
por: Tan, Laura A, et al.
Publicado: (2022)

The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)

μ Opioid receptor: novel antagonists and structural modeling
por: Kaserer, Teresa, et al.
Publicado: (2016)

Methylnaltrexone: Peripherally Acting µ-Opioid Receptor Antagonist
por: Uritsky, Tanya J.
Publicado: (2019)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
por: Levy-Cooperman, N., et al.
Publicado: (2016)

Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible μ Opioid Receptor Antagonist Effects
por: Moynihan, Humphrey A., et al.
Publicado: (2012)

Crystal structure of the μ-opioid receptor bound to a morphinan antagonist
por: Manglik, Aashish, et al.
Publicado: (2012)

Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers
por: Toledo, Frederico G. S., et al.
Publicado: (2021)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
por: Sun, Lei, et al.
Publicado: (2019)

Distinct Profiles of Desensitization of µ-Opioid Receptors Caused by Remifentanil or Fentanyl: In Vitro Assay with Cells and Three-Dimensional Structural Analyses
por: Uezono, Eiko, et al.
Publicado: (2023)

The place for short-acting opioids: special emphasis on remifentanil
por: Wilhelm, Wolfram, et al.
Publicado: (2008)

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation
por: Floettmann, Eike, et al.
Publicado: (2017)

The Use of Peripheral μ-Opioid Receptor Antagonists (PAMORA) in the Management of Opioid-Induced Constipation: An Update on Their Efficacy and Safety
por: Pergolizzi Jr, Joseph V, et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

Intraoperative use of remifentanil and opioid induced hyperalgesia/acute opioid tolerance: systematic review
por: Kim, Sang Hun, et al.
Publicado: (2014)

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy
por: Pergolizzi, Joseph V, et al.
Publicado: (2017)

Peripherally Acting μ-Opioid Receptor Antagonists for the Treatment of Opioid-Related Side Effects: Mechanism of Action and Clinical Implications
por: Streicher, John M., et al.
Publicado: (2017)

Effects of µ-Opioid Receptor Gene Polymorphism on Postoperative Nausea and Vomiting in Patients Undergoing General Anesthesia with Remifentanil: Double Blinded Randomized Trial
por: Lee, Seung-Hyun, et al.
Publicado: (2015)

Could remifentanil reduce duration of mechanical ventilation in comparison with other opioids for mechanically ventilated patients? A systematic review and meta-analysis
por: Zhu, Yibing, et al.
Publicado: (2017)

Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
por: Sun, Lei, et al.
Publicado: (2019)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

Peripherally Acting μ-Opioid Receptor Antagonists in the Management of Postoperative Ileus: a Clinical Review
por: Chamie, Karim, et al.
Publicado: (2020)

Pharmacologic effects of naldemedine, a peripherally acting μ‐opioid receptor antagonist, in in vitro and in vivo models of opioid‐induced constipation
por: Kanemasa, Toshiyuki, et al.
Publicado: (2019)

Remifentanil infusion as a modality for opioid-based anaesthesia in paediatric practice
por: Abdel Hamid, Ahmed Mostafa, et al.
Publicado: (2010)

A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine
por: Srisurapanont, Manit, et al.
Publicado: (2021)

Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis
por: Peng, Zhenlei, et al.
Publicado: (2023)

Enhancement of Meditation Analgesia by Opioid Antagonist in Experienced Meditators
por: May, Lisa M., et al.
Publicado: (2018)

Efficacy and Safety of Peripherally Acting μ-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review
por: Rekatsina, Martina, et al.
Publicado: (2021)

Discovery of SHR9352: A Highly Potent G Protein-Biased μ-Opioid Receptor Agonist
por: Li, Xin, et al.
Publicado: (2017)

Blood–brain barrier: mechanisms governing permeability and interaction with peripherally acting μ-opioid receptor antagonists
por: Viscusi, Eugene R, et al.
Publicado: (2020)

The pharmacokinetic interaction between nasally administered naloxone and the opioid remifentanil in human volunteers
por: Tylleskar, Ida, et al.
Publicado: (2021)

Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination
por: Sun, Lei, et al.
Publicado: (2020)

Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor
por: Ben Haddou, Tanila, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ud03ofp1k0949it3l72ns40tvv